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ABSTRACT 
Objective: To offer recommendations on identification of disease progression, 
treatment management strategies, and suggestions on timing of initiating and 
discontinuing specific CRPC treatments. 
Materials and Methods: The RADAR II [Prostate Cancer Radiographic 
Assessments for Detection of Advanced Recurrence] Working Group convened 
to provide guidance on sequencing, combination, or layering of approved 
treatments for mCRPC based on available data and clinical experience. 
Results: A consensus was developed to address important questions on 
mCRPC patient management. 
Conclusions: In the absence of large scale clinical trials, the Working Group 
recommends that patients may best be managed with a layered approach of 
approved therapies with unique or complimentary mechanisms of action. 
 
Key Words: castration-resistant prostate cancer, guidelines, treatment, 
sequencing, combination, layering  
 
 (Main body word count limit: 4,000. Currently 3,929) 
INTRODUCTION 
 
Castration-resistant prostate cancer (CRPC) is a progressive disease 
(total testosterone <50 ng/dL) in men and is associated with one or more of the 
following: symptomatic, radiographic, or prostate-specific antigen (PSA) 
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progression.1 Survival with CRPC has dramatically improved over the past 
decade due to the availability of multiple new therapeutics. These treatment 
options include an androgen biosynthesis inhibitor (abiraterone acetate) and an 
androgen receptor antagonist (enzalutamide), an immunotherapy (sipuleucel-T), 
a targeted alpha therapy (radium-223), and chemotherapeutic agents (docetaxel 
and cabazitaxel). Nevertheless, the management of metastatic castration-
resistant prostate cancer (mCRPC) poses a significant challenge due to disease 
heterogeneity and the invariable development of molecular, proteomic, and 
genomic patterns of resistance.  
 
While the recent therapeutic advances have shown a significant survival 
benefit in monotherapy trials in patients with mCRPC, optimal use (eg, 
combination and sequencing) of chemotherapy, second-generation androgen 
pathway inhibitors, immunotherapy, and a targeted alpha therapy to achieve 
maximum clinical benefit has not been established. There is a paucity of head-to-
head trials to compare these new agents and no trials have yet been published 
comparing combinations to other combinations or monotherapy. As a result, 
there is no consensus in the current guidelines on the appropriate sequence of 
the available therapeutic options.2-4 In addition, the lack of validated predictive 
biomarkers of survival may delay treatment optimization. Therefore, decisions 
regarding treatment are made on the basis of limited nonrandomized 
comparisons, consideration of safety and tolerability, assumptions about the risks 
and benefits of combining agents with potentially complementary mechanisms of 
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action, potential for overlapping toxicities, and anecdotal experience. In addition, 
logistics regarding access to therapeutics as well as reimbursement policies may 
vary depending upon global and regional locations. 
 
In the absence of a consensus on timing, methods, and frequency of 
imaging in clinical practice, the Working Group (Prostate Cancer Radiographic 
Assessments for Detection of Advanced Recurrence [RADAR I] Group) of 
medical oncologists, radiation oncologists, urologists, and a nuclear medicine 
radiologist convened to review available data and provide recommendations for 
early identification of metastases in patients with prostate cancer.5 Many of the 
same participants from the RADAR I Group collaborated in this consensus group 
to discuss the management of disease progression in patients with CRPC. One 
key objective of this Working Group was to provide a consensus regarding 
sequencing, combination, and “therapeutic layering.” Therapeutic layering is 
hereafter defined as a clinical point where one or more agent(s) are added onto 
an existing therapy. In forming these recommendations, the Working Group took 
into account the different treatment possibilities, trial data, existing guidelines, 
and real-world, practical considerations tempered by the clinical experience of 
the members.  
 
REVIEW OF RADAR I RECOMMENDATIONS: IMAGING 
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Briefly, the RADAR I Group previously made recommendations regarding 
the timing and frequency of imaging among different patient groups with prostate 
cancer in order to identify metastatic disease early.5 The RADAR I Group 
cautioned against overutilization of imaging in clinical practice. Imaging in clinical 
practice should not reflect the timing or frequency of imaging in clinical trials, but 
rather should be utilized when therapeutic selection can be affected by results (ie, 
we emphasize the importance of diagnostic recommendations in order to 
optimize clinical utility). Imaging should be initiated when 1) considering starting 
therapy, 2) prior to changing therapy to establish a new baseline, and 3) after 
treatment has been completed to monitor disease progression. The discordance 
between the response of PSA and results of radiographic imaging has created 
confusion in identifying disease progression. The RADAR I Group recommends 
PSA trends and clinical context to be most important. For example, PSA doubling 
time (PSADT) is a very consistent predictor of aggressive disease progression in 
different disease states, but the greatest absolute utility of PSA is in the 
biochemical recurrence setting.6 Therefore, the recommendation by the RADAR I 
Group is to also perform subsequent imaging when clinical or consistent and 
convincing biochemical progression is identified. As a follow up to the previous 
recommendations, the RADAR II group recognizes that radiolabeled choline 
positron emission tomography/computed tomography (PET/CT) was recently 
determined to be more sensitive than conventional imaging (eg, ultrasound, CT 
of abdomen and pelvis, and bone scans) in select patients with biochemical 
recurrence.7 The 2016 National Comprehensive Cancer Network (NCCN) 
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guidelines provide updated recommendations for the use of radiolabeled choline 
PET/CT in these select patients.4 More recently, 18F-FACBC (Axumin) PET/CT 
was found to be superior in detection to 11C-choline PET/CT scanning in 
patients with biochemical recurrence,8 and this new agent was approved by the 
Food and Drug Administration (FDA) in May 2016. 
 
CURRENT TREATMENT LANDSCAPE 
 
Currently, mCRPC is incurable. Therefore, the goal of treatment is to 
extend life and provide the best possible quality of life (QOL) for patients with 
mCRPC for as long as possible.2 Since the approval of docetaxel in the United 
States in 2004, 5 new agents have achieved FDA approval for the treatment of 
mCRPC with an ability to prolong survival (Table 1). Although cabazitaxel is 
indicated only for the treatment of patients with mCRPC who have received prior 
treatment with a docetaxel-containing regimen, the other agents may be 
employed for first-line or subsequent therapy. Current treatment guidelines 
provide a list of available agents with limited recommendations regarding any 
order of sequence, combination, or layering (Table 2). The Working Group 
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recognizes that all treatment interventions for CRPC are technically layering of 
therapy since agents are added to the foundation of androgen deprivation 
therapy (ADT). ADT is continued even in the setting of CRPC where androgen-
sensitive clones exist, and continuing ADT has become standard to avoid 
symptomatic and PSA progression from these clones.9 Hence, the term 
“therapeutic layering” was devised to describe a situation whereby a therapy is 
being used and one or more additional agent(s) are added. This is unique from 
“combination therapy” where 2 or more therapies are initiated simultaneously.  At 
this time, the Working Group recommends considering therapeutic layering of 
certain new agents in patients with mCRPC when appropriate (Figure).  
 
 
 
QUESTIONS CONSIDERED BY THE WORKING GROUP 
 
The RADAR II Working Group first addressed questions regarding disease 
progression: 
 
 How is progression defined? What is the best way to determine 
progression while a patient is being treated with therapeutic agents with 
biologically distinct mechanisms of action? 
Page 10 of 41
11 
 
 
The Working Group also made recommendations regarding initiating and 
discontinuing therapeutic agents: 
 
 How early should treatment be initiated in patients with mCRPC? Which 
agents should be considered for use early in the disease process? 
 When should therapy be changed? Should treatment continue beyond 
progression? If yes, with which agents?  
 When should treatment be started and when should treatment be 
discontinued for each specific therapeutic agent?  
 Should second-generation androgen pathway inhibitors (abiraterone or 
enzalutamide) be used sequentially? 
 
The Working Group’s recommendations are as follows: 
How is progression defined? What is the best way to determine 
progression while a patient is being treated with therapeutic agents with 
biologically distinct mechanisms of action? 
 
Recommendation: The Working Group defined progression of mCRPC as a 
convincing and consistent rise in PSA, evidence of radiographic progression, or 
the presence of clinical symptoms while the patient is on therapy. Recognizing 
that the different agents have unique mechanisms of action, Table 3 outlines 
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recommended imaging and biomarkers to follow in order to determine 
progression while a patient is being treated with each therapeutic agent. In the 
absence of validated biomarkers for disease progression, close monitoring of 
patient symptoms and imaging are critical to ensure a patient is afforded the 
ability to receive alternative treatment to increase life expectancy and maintain or 
improve QOL. 
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How early should treatment be initiated in patients with mCRPC? Which agents 
should be considered for use early in the disease process? 
 
Recommendation: Although the topic of hormone-sensitive disease is technically 
outside of the topic of this consensus statement, recent data from the CHAARTED 
[ChemoHormonal therapy versus Androgen Ablation Randomized Trial for Extensive 
Disease in prostate cancer], STAMPEDE [Systemic Therapy in Advancing or Metastatic 
Prostate cancer: Evaluation of Drug Efficacy], and GETUG-AFU-15 trials have potential 
to affect subsequent therapy in the mCRPC state. These 3 trials collectively 
demonstrate that the early use of docetaxel in patients diagnosed with metastatic 
androgen sensitive disease significantly improves progression-free survival21-23 and 
OS.21,22 The trials were designed to add (therapeutically layer) docetaxel to (on top of) 
ADT, as patients were allowed to enroll within either 4 (CHAARTED), 3 (STAMPEDE), 
or 2 (GETUG 15-AFU-15) months of initiation of ADT. Although it is unclear whether 
early use of chemotherapy in the androgen-sensitive setting affect the survival gains of 
delayed use of chemotherapy in mCRPC, consideration of subsequent treatment when 
a patient does reach mCRPC was a discussion topic. Specifically, after a patient 
progresses after receiving prior ADT with docetaxel, should docetaxel be utilized again, 
and if so, when? Also if a patient has never received chemotherapy before, should 
chemotherapy be administered early in mCRPC, extrapolating from early use of 
chemotherapy in the androgen-sensitive setting? 
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The consensus from the Working Group is that chemotherapy should be initiated 
early in hormonally naive, newly diagnosed metastatic prostate cancer patients with 
high-volume disease.21 In low volume disease, chemotherapy has not shown a benefit 
in hormonally naive newly diagnosed patients.24 For mCRPC, we generally do not 
recommend starting with chemotherapy first. The anticipated median survival benefit 
from docetaxel in the mCRPC setting is approximately 2 months,18,19 an absolute 
number much smaller than the median 13-month and 22-month benefit seen in 
CHAARTED and STAMPEDE for the metastatic populations, respectively. Therefore, to 
maintain good QOL, it may be logical to reserve chemotherapy for a more symptomatic 
mCRPC patient where survival benefit will be coupled with an additional pain palliative 
benefit. This recommendation is consistent with that of the St. Gallen Advanced 
Prostate Cancer Consensus Conference, which did not recommend docetaxel 
chemotherapy as first-line therapy for otherwise healthy asymptomatic/minimally 
symptomatic men with mCRPC.25 However, the St. Gallen group did believe that 
docetaxel should be administered prior to other options in otherwise healthy 
symptomatic patients who had a short duration response (<12 months) to primary 
ADT.25 If docetaxel was administered in the androgen sensitive setting previously, our 
Working Group recommends retreatment with docetaxel if the time to relapse was over 
12 months and the patient does not have persisting neuropathy from the docetaxel, 
otherwise cabazitaxel should be considered. Because definitive clinical data does not 
exist, the Working Group recommends initiating basic investigations and clinical trials to 
fully establish if taxane resistance patterns exist or emerge in this population. 
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Immunotherapy 
 
Immunotherapy with sipuleucel-Ta [FOOTNOTE: aAvailable only in the US] 
should be considered for first-line therapy in patients with mCRPC who are 
asymptomatic, have low disease burden, and who exhibit indolent disease 
characteristics.26,27 Early introduction of sipuleucel-T is supported by a posthoc analysis 
of results from the IMPACT [Immunotherapy for Prostate Adenocarcinoma Treatment] 
trial, which showed patients with lower baseline PSA values achieved a greater 
magnitude of OS benefit with sipuleucel-T.12 In the postchemotherapy setting, 
sipuleucel-T can also be administered with survival benefit; however, it is important to 
recognize that this was a unique subset of patients from the IMPACT trial who had 
shown an excellent response to previous chemotherapy and were eligible to receive 
sipuleucel-T after a significant chemotherapy holiday.28 
 
The Working Group recommends that immunotherapy with sipuleucel-T be 
considered for all newly diagnosed asymptomatic/minimally symptomatic mCRPC 
patients with low tumor burden.12 The duration of therapy is fixed with 3 doses and can 
be completed in 5 weeks (Table 3). In recent clinical trials, sipuleucel-T has been 
combined with enzalutamide (ClinicalTrials.gov Identifier: NCT01981122), abiraterone 
(ClinicalTrials.gov Identifier: NCT01487863), and radium-223.29 The Working Group 
encourages continued clinical exploration of biologically rational combinations with 
sipuleucel-T including other immunotherapies. 
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Second-Generation Androgen Pathway Inhibitors 
 
Current guidelines recommend the early initiation of androgen pathway inhibitors 
(ie, abiraterone or enzalutamide) for patients either with or without minimal symptoms in 
the prechemotherapy setting.4 The Working Group suggests initiating second-
generation androgen pathway inhibitors (abiteratone, enzalutamide) following 
immunotherapy in the setting of biochemical or clinical progression in this 
prechemotherapy setting. Recognizing that not all patients are ideal candidates for 
sipuleucel-T, the Working Group suggests starting first with a second-generation 
androgen pathway inhibitor in that patient population. 
 
Targeted Alpha Therapy 
 
Following a second-generation androgen pathway inhibitor, radium-223 should 
be considered for patients with bone metastases upon the emergence of signs and 
symptoms (ie, fatigue, impaired mobility, previous or current bone pain). The risk of 
bone metastatic disease can be independently predicted by alkaline phosphatase (ALP) 
and PSA.30 In phase 3 trials with enzalutamide and abiraterone, a subsequent 
decrement in QOL occurred soon after PSA progression, even in the absence of 
radiographic progression13,31; therefore, it is reasonable to consider radium-223 during 
or soon after PSA progression on those agents. In the phase 3 ALSYMPCA trial, 
radium-223 demonstrated OS efficacy in patients with progressive mCRPC with 2 or 
more bone metastases detected on skeletal scintigraphy and no known visceral 
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metastases.32 Subgroup analysis indicated that radium-223 had a significant OS benefit 
in patients with and without prior docetaxel treatment.32 In posthoc and retrospective 
analyses, improved results have been observed in patients who receive 5 or 6 doses of 
radium-223 compared with those who receive only 1 to 4 doses.33-35 Patients who 
receive radium-223 early in the course of disease are also more likely to receive all 6 
doses compared with those who are treated later in the disease process.36 Radium-223 
has an excellent safety profile and low risk for adverse effects on hematopoiesis,32 
making it worthwhile to consider in a minimally symptomatic patient prior to 
administration of chemotherapy. Radium-223 has also been tested concomitantly with 
chemotherapy,37,38 but more extensive trials are ongoing with radium-223 and second-
generation androgen pathway inhibitors (ClinicalTrials.gov Identifiers: NCT02043678; 
NCT02034552, NCT02194842).39,40 The Working Group advises that consideration be 
given to adding (therapeutic layering) radium-223 to androgen pathway inhibitors in 
patients with bone metastases and symptoms. 
 
When should therapy be changed? Should treatment continue beyond 
progression? If yes, with which agents? 
 
Recommendation: The Working Group recommends that changes in therapy should 
depend upon careful consideration of the mechanism of the therapeutic agent being 
used with the type of progression the patient is experiencing.  For example, agents that 
do not directly induce tumor cell apoptosis or inhibit the androgen axis may not have 
direct effect on PSA. Specifically, this would include agents like sipuleucel-T and 
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radium-223, as both offer survival benefit without consistent PSA declines. Changes 
based on PSA alone are not generally recommended, particularly in the setting of 
favorable PSA kinetics (ie, long PSADT). This view is also in agreement with the 
suggestions of the St. Gallen Advanced Prostate Cancer Consensus Conference, which 
cautioned against stopping treatments with a proven survival benefit on the basis of 
PSA progression alone.25 Additionally, the Prostate Cancer Clinical Trials Working 
Group 3 (PCWG3) emphasized the importance of distinguishing between first evidence 
of disease progression (perhaps by PSA rise) vs stopping treatment when there is no 
longer a clinical benefit.1 Altogether, the Working Group believes that symptomatic or 
radiographic progression are more reliable triggers for either therapeutic layering or 
change. PSA progression alone should prompt reimaging and may be a more reliable 
biologic indicator for therapeutic alteration or layering for the androgen pathway 
inhibitors.  
 
When should treatment be started and when should treatment be discontinued 
for each specific therapeutic agent? 
 
Recommendation: The recommendations of the Working Group also consider 
augmentation rather than switching treatment. These recommendations are based on 
the clonal diversity of mCRPC41 and the understanding that sequencing (ie, 
discontinuing current treatment when a new therapy is initiated) may allow clones 
suppressed by the current treatment clones to re-emerge or expand. Similar to 
therapeutic layering of (adding) a new agent to ADT with the development of CRPC, the 
Page 18 of 41
 19 
 
Working Group also considers therapeutic layering with agents used for known mCRPC. 
Table 3 outlines recommendations for when treatment should be added, stopped, or 
switched for each therapeutic agent. 
 
Should second-generation androgen pathway inhibitors (abiraterone or 
enzalutamide) be used sequentially? 
 
Recommendation: There is no advice in the current guidelines regarding the 
sequential use of second-generation androgen pathway inhibitors.4 The ideal sequence 
of abiraterone and enzalutamide has not yet been established, but several prospective 
trials are comparing single agent to double agent therapy. Retrospective studies 
suggest that the antitumor activity of abiraterone or enzalutamide is reduced when 
administered sequentially.42,43 The activity of abiraterone also appears to be reduced 
after prior treatment with either docetaxel or enzalutamide.44 Even when responses by 
PSA occur, the magnitude and duration of response to the second-line androgen 
pathway inhibitor may be diminished, relative to the first androgen pathway inhibitor. 
Although there are less data in the prechemotherapy setting, enzalutamide has shown 
limited activity when administered subsequent to abiraterone.43 Preclinical evidence 
suggests that cross-resistance may also exist between cabazitaxel and the androgen 
pathway inhibitors.45 The cross-resistance between taxanes and abiraterone or 
enzalutamide may not be distinct, particularly as microtubules may have an important 
role of shuttling androgen receptor to the nucleus.46 Taxane efficacy may be reduced in 
tumors that have developed resistance to androgen receptor pathway inhibition, as 
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demonstrated in patients with mCRPC who had early development of castration 
resistance (<12 months), had a shorter time to progression, and shorter OS with 
docetaxel treatment compared with patients with more prolonged sensitivity to androgen 
axis suppression.47 The Working Group, however, noted that the shorter efficacy of 
subsequent therapy to docetaxel may also be due to more advanced disease rather 
than prior therapeutic exposure. A prospective evaluation showed an association 
between detection of androgen-receptor splice variant 7 (AR-V7) in messenger RNA 
circulating tumor cells and resistance to enzalutamide or abiraterone from patients with 
CRPC.48 The results from a recent cross-sectional cohort study demonstrated 
circulating tumor cell nuclear expression of AR-V7 protein in men with mCRPC as a 
treatment-specific biomarker, which is associated with superior survival on taxane 
therapy over second-generation androgen pathway inhibitors.49 Technologies to detect 
AR-V7 may soon be commercially available for use, although the utility of AR-V7 as a 
“predictive biomarker” still requires further validation. Based on the current state of the 
data, the consensus from the Working Group was that switching therapy from one 
second-generation androgen pathway inhibitor to another after progression on the first 
agent is not recommended in most situations. However, a switch from one second-
generation androgen pathway inhibitor to another may be considered if there is a 
prolonged treatment response (>12 months) to the first agent, or if the patient is a poor 
candidate for, or declines on, taxane therapy. The question of whether to switch from 
one second-generation androgen pathway inhibitor directly to another, or whether to 
move on to an agent which does not target the androgen pathway (radium-223 or  
chemotherapy) needs to be answered in prospective, randomized clinical trials. The 
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Working Group also recommends the layering of radium-223 to a second-generation 
androgen pathway inhibitor upon first sign of progression as an option. It is also 
possible that if chemotherapy is administered between one novel hormonal agent and 
another, there may be resensitization of the patient’s tumor to second-generation 
androgen pathway inhibitors. 
 
FOCUS ON THERAPEUTIC LAYERS 
 
Important questions remain unanswered, such as what constitutes the most 
effective sequence, combination, or therapeutic layer in mCRPC. With 6 approved 
agents that prolong survival for mCRPC, exploration of every single duo in a 
combination or layering trial is not possible. However, the potential benefit of combining 
agents for the treatment of patients with mCRPC has been assessed in several small-
scale studies and additional larger trials are currently ongoing. Trials are ongoing to 
determine optimal timing, sequence, and combination of these agents (ClinicalTrials.gov 
Identifiers: NCT01650194, NCT02522715, NCT01308567, NCT02254785, 
NCT02379390). Therefore, clinical trial participation should be offered to patients to 
advance the understanding of the efficacy of combinations, and more effort should be 
placed into therapeutic layering to attempt to further improve patient outcomes. 
 
The Working Group believes that the easiest agents to therapeutically layer are 
the androgen pathway inhibitors. These agents are currently layered on top of ADT at 
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the outset of CRPC. The Working Group believes that second-generation androgen 
pathway inhibitors form an additional layer of therapy that can be combined with other 
partners, and may be generally less toxic in additional combinations. Several such 
combination trials in men with mCRPC are ongoing with chemotherapy, such as 
enzalutamide in combination with cabazitaxel (ClinicalTrials.gov Identifier: 
NCT02522715). 
 
Concurrent administration of radium-223 and second-generation androgen 
pathway inhibitors appears to be well tolerated with similar toxicities compared with 
standard administration of radium-223 alone.50 Data from 2 expanded access studies 
provided preliminary evidence that OS may be significantly longer in patients treated 
with concomitant radium-223 and abiraterone (vs radium-223 alone), as well as patients 
treated with concomitant radium-223 and denosumab (vs radium-223 alone).39,50 A 
randomized phase 2a study of radium-223 with abiraterone or enzalutamide in patients 
with mCRPC is underway (ClinicalTrials.gov Identifier: NCT02034552). Two phase 3 
trials of radium-223 in combination with abiraterone or enzalutamide in asymptomatic or 
mildly symptomatic chemotherapy-naive patients with bone-predominant mCRPC are 
also currently ongoing (ClinicalTrials.gov Identifier: NCT02043678, NCT02194842).40 
Evidence from a posthoc analysis of concomitant bone-targeted supportive therapy 
(BTT) in chemotherapy-naive mCRPC patients treated with abiraterone acetate plus 
low-dose prednisone vs prednisone alone revealed that concomitant BTT significantly 
improved OS, increased the time to Eastern Cooperative Oncology Group (ECOG) 
deterioration, and time to opiate use for cancer-related pain.51 
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Sipuleucel-T is also being evaluated as part of combination treatment with newer 
agents. A phase 2 open-label study has assessed the effects of concurrent or 
sequential administration of abiraterone acetate plus prednisone on sipuleucel-T 
manufacture and immune response in 69 patients with mCRPC. Results indicated that 
sipuleucel-T can be successfully administered during concurrent administration of 
abiraterone plus prednisone without altering the immunologic effects or parameters that 
have been correlated with survival benefit from sipuleucel-T.52 An ongoing randomized, 
open-label study is also evaluating the effects of sipuleucel-T when administered 
concurrently or sequentially with enzalutamide (ClinicalTrials.gov Identifier: 
NCT01981122).53 Sipuleucel-T is also being combined with radium-223 in a trial of 
asymptomatic or minimally symptomatic patients with CRPC and bone metastases.29 
 
CONCLUSIONS 
 
There have been great strides in the management of mCRPC in the past 5 
years.5 However, clinicians who evaluate and manage patients with mCRPC face the 
challenging task of selecting a treatment approach that will optimize their patient’s 
outcomes. These selections must often be made without the results from large-scale 
randomized, controlled clinical trials evaluating combination, sequential, or direct 
comparator protocols. Given the approved therapeutics and their phase 3 registrational 
trials, extrapolation of clinical data to a real-world setting is difficult due to the specific 
inclusion and exclusion criteria for these clinical studies. There is no agreement on an 
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ideal therapeutic CRPC sequence for all patients. We believe that patients with mCRPC 
will ultimately be best managed with different agents, particularly those with unique and 
complementary mechanisms of action that may be used together in order to avoid 
inducing cross-resistance. Providing additional evidence about the efficacy, safety, and 
tolerability of combination regimens, and enhanced approaches for identifying patients 
most suited for specific treatments, remain an important clinical trial need. 
 
Combining antineoplastic agents is not a novel concept. Successful cure rates for 
lymphoma, testis, gastrointestinal, lung, and breast cancers, and certain leukemias 
have been attained by utilizing combination therapy. Ultimately, selection of optimal 
treatment may increasingly depend on molecular characterization and genotyping as 
well as patients’ clinical characteristics. 
 
The RADAR II Working Group believes that the guidance provided in this paper 
is consistent with currently available clinical trial results, and we anticipate additional 
data to further inform combining and/or sequencing CRPC therapeutic agents. When 
initiating treatment early, consideration should be given to how any chosen therapy may 
potentially impact subsequent treatments. However, it must be acknowledged that 
clinical trials might never address all possible options for patient management given the 
large number of agents now available as well as the potential addition of other unique 
therapeutics. Therefore, while the recommendations of the RADAR II group are based 
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on the available trial literature and real-world experience, optimal patient care will 
continue to demand the clinical judgment of each treating physician. 
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Figure. Opportunities for therapeutic layering in mCRPCa 
aClinicalTrials.gov Identifiers: 
NCT01487863, NCT01981122, NCT02034552, NCT02288247, NCT02522715. 
bNot eligible if visceral metastasis is present. 
mCRPC, metastatic castration-resistant prostate cancer. 
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Table 1. Agents approved for the treatment of mCRPC in the US  
Therapy Sipuleucel-T Docetaxel Abiraterone 
acetate Enzalutamide 
Radium-
223 
Indication M1 CRPC: 
asymptomatic,  
minimally 
symptomatic 
M1 CRPC M1 CRPC M1 CRPC M1 CRPC: 
symptomatic 
with bone 
metastases 
and no 
visceral 
metastases 
Class of 
therapy 
Autologous 
immunotherapy 
Chemotherapy Hormonal 
therapy 
Hormonal 
therapy 
Targeted 
alpha 
therapy 
Efficacy 
parameter 
     
OS ✓ ✓ ✓ ✓ ✓ 
PFS  ✓ ✓ 
(radiographic) 
✓  
(radiographic) 
 
Reduced time 
to first SSE  
    ✓ 
Steroids 
required 
No Yes Yes No No 
Liver/kidney 
monitoring  
or dose 
No Yes Yes No No 
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adjustment 
required 
Dosing 
schedule 
3 cycles  
(leukapheresis  
+ infusion)  
about 2 weeks 
apart  
10 cycles,  
every 3 weeks 
4 tablets 
once daily 
with BID 
concomitant 
steroids 
4 capsules 
once daily  
6 cycles,  
every 4 
weeks 
Route of 
administration 
Intravenous Intravenous Oral Oral Intravenous 
BID, twice daily; CRPC, castration-resistant prostate cancer; M1, evidence of metastatic disease; mCRPC, metastatic 
castration-resistant prostate cancer; OS, overall survival; PFS, progression-free survival; SSE, symptomatic skeletal event; 
US, United States. 
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Table 2. Current guidance for the treatment of CRPC  
Stage 
National 
Comprehens
ive Cancer 
Network 
(NCCN)4 
 
American 
Urological 
Association 
(AUA)3 
American 
Society of 
Clinical 
Oncology 
(ASCO)2 
European 
Society for 
Medical 
Oncology 
(ESMO)10 
Canadian 
Urological 
Association -
Canadian 
Urologic 
Oncology 
Group (CUA-
CUOG)11 
M0 
   Docetaxel 
(patients with 
local 
progression 
and no 
possibility for 
local 
treatment) 
 
M1 
Docetaxel 
Mitoxantrone 
Sipuleucel-T 
Abiraterone 
Enzalutamide 
Cabazitaxel 
Radium-223 
(with bone 
metastases)  
Docetaxel 
Mitoxantrone 
Sipuleucel-T 
Abiraterone 
Enzalutamide 
Cabazitaxel 
Radium-223 
(with bone 
metastases)  
Docetaxel 
Mitoxantrone 
Sipuleucel-T 
Abiraterone 
Enzalutamide 
Cabazitaxel 
Radium-223 
(with bone 
metastases)  
Docetaxel 
Abirateronea 
Enzalutamidea 
Cabazitaxel 
Sipuleucel-Ta 
Radium-223
b 
 
Docetaxel 
Abiraterone 
Enzalutamide 
Cabazitaxel 
Radium-223 
(with bone 
metastases)  
aPatients who are asymptomatic/mildly symptomatic men with chemotherapy-naive 
mCRPC. 
bPatients with bone-predominant, symptomatic mCRPC. 
  
CRPC, castration-resistant prostate cancer; mCRPC, metastatic castration-resistant 
prostate cancer. 
 
Page 37 of 41
 38 
 
Table 3. Treatment recommendations for patients with mCRPC TxNx-M1 
 Initiate/Add Imaging/Biomarkers 
to Follow 
Stop/Switch/Add 
Treatment   
Consensus 
Commentary 
Immunotherapy 
(sipuleucel-T) 
• Should be considered 
for all newly 
metastatic CRPC 
patients with low 
tumor burden 
(asymptomatic/minima
lly symptomatic 
patients) 
- Can be used 
after other 
therapies if 
patient had an 
outstanding 
response to the 
prior therapy  
 
• PSA<22 prior to 
initiation may provide 
best survival 
outcomes12 
• Improvements in 
PSA or imaging 
should generally not 
be expected 
 
Duration of therapy is 
fixed to 3 doses  
• Anti-PAP antibody 
may be detectable 
for 8 to 10 years 
postvaccination13 
 
Androgen pathway 
inhibitors 
(abiraterone acetate 
and enzalutamide) 
• Upon consecutive PSA 
rises  
• Early initiation is 
associated with greater 
benefit4 
• Consider initiating 
therapy following 
sipuleucel-T upon 
• Consecutive rise in 
PSA levelsa indicative 
of resistance 
• AR full length and AR 
splice variant 
expression in 
circulating tumor cells 
are potential 
biomarkers still under 
• Symptomatic 
progression 
• Radiographic 
progression  
• Consider reimaging 
with consecutive and 
convincing PSA rises 
and either proceed with 
• Therapeutic 
layering with 
radium-223 as 
appropriate 
• Switch to taxane-
based therapy 
• PSA and ALP may 
rise before falling 
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biochemical or clinical 
progression 
• If patient not a good 
candidate for 
sipuleucel-T, start with 
abiraterone or 
enzalutamide 
evaluation and 
requiring validation 
therapeutic layering or 
switch 
with abiraterone 
(wait 3 months 
before making 
decision on these 
markers) 
• Bone scan healing 
flare has been 
described14 
 
Targeted alpha 
therapy (radium-223) 
 
• Can be introduced at 
the first sign of 
progression on 
androgen pathway 
inhibitors for patients 
with bone metastases 
and symptoms  
• Strong consideration 
for use prior to 
chemotherapy 
- Favorable safety 
profile and low 
risk for adverse 
effects on 
hematopoiesis 
• PSA changes do not 
correspond with 
survival outcomes 
• ALP is a potential 
response biomarker 
 
 
• May be therapeutically 
layered onto 
abiraterone or 
enzalutamide  
• All 6 cycles should be 
given for maximal 
benefit 
• If given just with ADT, 
therapeutic layering of 
abiraterone or 
enzalutamide can be 
considered with: 
- Appearance of 
new symptoms 
- Rapid growth of 
lymph nodes 
- Emergence of 
visceral disease 
 
• Consider radium-
223 earlier in 
therapy  
• Palliative 
radiotherapy can 
be used before, 
during, or after 
radium-223 
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Chemotherapy  • Generally administer 
after abiraterone 
and/or enzalutamide 
and radium-223 
- Consider 
starting earlier in 
patients with 
visceral 
metastases, 
rapidly 
progressive 
symptomatic 
disease, or 
those with no or 
very short 
response to 
ADT/second-
generation 
androgen 
pathway 
inhibitors 
- Early 
chemotherapy 
may influence 
the efficacy of 
latter lines of 
treatment 
• For 
neuroendocrine/small 
cell carcinoma or 
aggressive variants, 
use platinum 
• Imaging, PSA, ALP, 
LDH should be 
obtained prior to 
therapy 
• Imaging if clinical 
deterioration, 
regardless of PSA5 
 For patients with a 
known DNA damage 
repair alteration (eg, 
BRCA1 or 2),15,16 
agents that induce 
double-strand DNA 
breaks should be 
considered (eg, 
platinum, radium-
223 or 
mitoxantrone).17 
PARP inhibitors are 
being explored in 
this setting 
(ClinicalTrials.gov 
Identifier 
NCT01972217; 
NCT02500901). 
• Stopping point is with 
radiographic or clinical 
progression, but it is 
unclear if PSA 
progression should be 
used as well 
• Phase 3 docetaxel trials 
allowed up to 10 
cycles18,19 
• Cabazitaxel should be 
administered in patients 
who previously 
progressed or were 
intolerant of docetaxel 
 
• May have activity in 
patients with AR 
splice variants20 
• PSA may first rise 
before falling  
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combination 
chemotherapy 
regimens 
 
aPSA alone should not be used. 
 
ADT, androgen deprivation therapy; ALP, alkaline phosphatase; AR, androgen receptor; LDH, lactate dehydrogenase; 
mCRPC, metastatic castration-resistant prostate cancer; PAP, prostatic acid phosphatase; PARP, poly ADP ribose 
polymerase; PSA, prostate-specific antigen. 
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